Stonnington Group’s Gilead Sciences GILD Stock Holding History

Stonnington Group’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$1.06M	Sell	12,751 -2,500	-16%	-$207K	0.28%	92
2022 Q4	$1.33M	Sell	15,251 -3,829	-20%	-$303K	0.37%	72
2022 Q3	$1.26M	Buy	19,080 +8,125	+74%	+$512K	0.36%	73
2022 Q2	$687K	Buy	10,955 +3,200	+41%	+$198K	0.18%	115
2022 Q1	$480K	Buy	7,755 +1,525	+24%	+$97.5K	0.11%	160
2021 Q4	$451K	Sell	6,230 -6,602	-51%	-$455K	0.1%	170
2021 Q3	$873K	Buy	12,832 +2,201	+21%	+$155K	0.2%	120
2021 Q2	$720K	Buy	10,631 +301	+3%	+$20.1K	0.16%	140
2021 Q1	$697K	Buy	+10,330	New	+$666K	0.17%	135

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stonnington Group's GILD Position: Q1 2023 in Review

Stonnington Group reduced its Gilead Sciences (GILD) stake by 16% in Q1 2023, selling an estimated $207K and leaving 12,751 shares worth $1.06M. The position accounts for 0.28% of the portfolio, ranked #92.

Stonnington Group first reported a position in GILD in Q1 2021 and has held it in 9 quarters since. The position peaked at $1.33M in Q4 2022. 1,735 funds tracked by Wall St. Rank hold GILD as of Q1 2023.

Stonnington Group held 12,751 shares of Gilead Sciences worth $1.06M as of Q1 2023.
Stonnington Group sold 2,500 Gilead Sciences shares in Q1 2023, an estimated $207K.
Gilead Sciences made up 0.28% of Stonnington Group's portfolio in Q1 2023, its #92 holding.
Stonnington Group first reported a position in Gilead Sciences in Q1 2021 and has held it in 9 quarters since.
Stonnington Group's Gilead Sciences position peaked at $1.33M in Q4 2022.
1,735 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2023.

Based on Stonnington Group's 13F filing for Q1 2023, filed 14 Apr 2023.